Clinical Trial

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

Study acronym: OraGrowtH211
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-03-30; most recent amendment 2024-02-14.
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-08-09
Trial Details
NCT Number NCT05796440
Lead Sponsor Lumos Pharma
Conditions Growth Hormone Deficiency
Enrollment 60 participants
Start Date 2023-08-01
Primary Completion 2028-03 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2024-02-15